Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
SUPN reported a Form 144 disclosure showing an insider disposition. The filing lists a sale by Todd Horich of 4,438 shares of Common Stock on 03/09/2026 for $239,652.00. The filing also shows restricted stock vesting entries of 394 shares on 02/23/2026 and 4,045 shares on 02/28/2026, each described as employee stock unit awards under a registered plan.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported routine equity compensation activity involving Performance Share Units that converted into common stock. He exercised derivative awards covering 38,640 Performance Share Units, receiving the same number of shares of common stock.
To cover tax withholding triggered by this vesting, 16,574 shares of common stock were withheld by the company at $54.73 per share, as described in the footnotes. After these transactions, Khattar held 1,228,644 shares of common stock directly and 1,005,600 shares indirectly through the KBT Trust, reflecting a substantial ongoing ownership position.
Supernus Pharmaceuticals SVP Frank Mottola reported a combination of equity compensation events and a small stock sale. He exercised 3,750 Performance Share Units into common stock, with 1,793 shares withheld by the company to cover taxes upon vesting of those units. Shortly after, he executed an open‑market sale of 1,623 common shares at $53.65 per share. Following these transactions, he directly owns 18,440 shares of common stock, reflecting a routine use of vested equity and partial share sale.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec exercised performance share units and settled related taxes in stock. On March 6, 2026, he converted awards into 6,000 shares of common stock, with 2,883 shares withheld at $54.73 per share for tax obligations, leaving 8,232 shares held directly.
Supernus Pharmaceuticals SVP, Commercial Operations William Todd Horich reported a series of stock transactions involving performance-based awards and subsequent sales. On March 6, 2026, he exercised performance share units to acquire 7,500 shares of common stock at $0.00 per share. In connection with this vesting, the company withheld 3,455 shares at about $54.73 per share to cover tax obligations, as disclosed in the footnotes.
He then executed open-market sales of common stock, selling 4,438 shares at $54.00 on March 9 and 4,439 shares at $55.00 on March 10. After these transactions, his directly held common stock position reported in this filing was reduced to zero shares. The filing shows no remaining derivative holdings, indicating all reported performance share units tied to these transactions were fully settled.
Supernus Pharmaceuticals SVP William Todd Horich filed an initial ownership report showing his equity holdings in the company. The filing lists multiple employee stock options on common stock with exercise prices such as $39.4000 and $27.9400, expiring between 2028 and 2036, as well as restricted stock units and performance share units that vest in four equal annual installments beginning on dates including February 23, 2024, February 22, 2025, February 19, 2026 and February 18, 2027. He also holds 4,832 shares of common stock directly.
SUPN filed a Form 144 reporting a proposed sale of 4,438 common shares.
The notice lists restricted stock vesting under a registered plan on 02/19/2026 (544 shares), 02/22/2026 (1,003 shares) and 02/23/2026 (2,891 shares). The broker/agent listed is Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of 1,623 shares of Common stock related to restricted stock vesting under a registered plan. The filing lists vesting dates of 01/12/2023, 02/22/2023, and 02/22/2024 with share counts 747, 461, and 415, respectively.
Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales. On March 6, 2026, he exercised a director stock option for 7,905 shares, receiving common stock at an exercise price of $0.00 per share, and held 36,064 shares afterward.
He then sold 10,000 shares of common stock on March 5, 2026 at a weighted average price of about $53.71, and a further 8,787 shares on March 6, 2026 at about $53.00, in open-market transactions. After these sales, he directly owned 27,277 shares of Supernus common stock.
Georges Gemayel filed a Form 144 reporting planned and recent sales of common stock. The filing lists a sale on 03/05/2026 of 10,000 shares for $537,117.00. It also shows securities to be sold from exercises: 3,787 shares by exercise on 03/06/2026 and 5,000 shares previously exercised on 03/04/2026.
The notice references an exercise under a registered plan and cash transactions; timing and cash‑flow recipients are described in the entries tied to those exercise dates.